Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab in Relapsed or Refractory Multiple Myeloma
NCT00675428Phase 2Terminated
- Sponsor
- Biogen
- Start
- Sep 2008
- Primary completion
- Dec 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of natalizumab in multiple myeloma (MM), sponsored by Biogen. Started Sep 2008; status: terminated.
02
Drugs
natalizumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00675428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00675428.